Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report published on Friday, Marketbeat reports. The brokerage issued a buy rating and a $6.00 target price on the stock. TRVI has been the subject of several other research reports. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics […]
More Stories
Good Energy Group’s (GOOD) Buy Rating Reiterated at Canaccord Genuity Group
Canaccord Genuity Group reaffirmed their buy rating on shares of Good Energy Group (LON:GOOD – Free Report) in a research...
Kingfisher (LON:KGF) PT Raised to GBX 350 at Deutsche Bank Aktiengesellschaft
Kingfisher (LON:KGF – Get Free Report) had its target price hoisted by research analysts at Deutsche Bank Aktiengesellschaft from GBX...
iShares Global Clean Energy ETF Sees Unusually High Options Volume (NASDAQ:ICLN)
iShares Global Clean Energy ETF (NASDAQ:ICLN – Get Free Report) was the recipient of unusually large options trading on Wednesday....
Suncor Energy (TSE:SU) PT Lowered to C$55.00 at Jefferies Financial Group
Suncor Energy (TSE:SU – Free Report) (NYSE:SU) had its price objective trimmed by Jefferies Financial Group from C$62.00 to C$55.00...
Primo Water (NYSE:PRMW) Stock Rating Lowered by StockNews.com
Primo Water (NYSE:PRMW – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold”...
PROS (NYSE:PRO) Stock Rating Lowered by StockNews.com
PROS (NYSE:PRO – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a...